Breaking News Instant updates and real-time market news.

ALNY

Alnylam

$92.76 /

+1.38 (+1.51%)

, REGN

Regeneron

$408.75 /

+2.18 (+0.54%)

07:11
04/08/19
04/08
07:11
04/08/19
07:11

Alnylam, Regeneron announce broad collaboration for RNai therapeutics

Alnylam Pharmaceuticals (ALNY) and Regeneron Pharmaceuticals (REGN) announced a collaboration to discover, develop and commercialize new RNA interference therapeutics for a broad range of diseases by addressing disease targets expressed in the eye and central nervous system, in addition to a select number of targets expressed in the liver. The collaboration will leverage both companies' scientific and technological expertise and will build on Alnylam's recent preclinical data showing potent and highly durable delivery of RNAi therapeutics to achieve target gene silencing in the eye and CNS. The collaboration will also benefit from Regeneron's industry-leading VelociSuite technologies and capabilities from the Regeneron Genetics Center. Under the terms of the alliance, Alnylam will work exclusively with Regeneron to discover RNAi therapeutics for eye and CNS diseases. Regeneron will lead development and commercialization for all programs targeting eye diseases, with Alnylam entitled to potential milestone and royalty payments. The companies will jointly advance and alternate leadership on CNS programs, with the lead party retaining global development and commercial responsibility. For CNS programs, both companies will have the option at candidate selection to participate equally in potential future profits of programs led by the other party. The collaboration also includes a select number of RNAi therapeutic programs designed to target genes expressed in the liver, which can influence a wide variety of diseases throughout the body. These programs include a planned joint effort evaluating anti-C5 antibody-siRNA combinations for C5 complement-mediated diseases including evaluating the combination of Regeneron's pozelimab, currently in Phase 1 development, with Alnylam's cemdisiran, currently in Phase 2 development. Alnylam will retain control of cemdisiran monotherapy development, and Regeneron will lead combination development. The parties will equally share investment and potential future profits on the monotherapy program, and Alnylam will receive royalties on any potential combination product sales. For all other alliance liver programs, the parties will alternate leadership and participate equally in potential profits. The companies will continue their previously-announced collaboration to identify RNAi therapeutics for the chronic liver disease nonalcoholic steatohepatitis based on novel RGC findings. Alnylam retains broad global rights to all of its other unpartnered liver-directed clinical and preclinical pipeline programs. Regeneron has agreed to make a $400M upfront payment to Alnylam and to purchase $400M of Alnylam equity at a price per share of $90.00, based on the volume-weighted average price over the last fifteen-trading-day period. Alnylam is eligible to receive up to an additional $200M in milestone payments upon achievement of certain criteria during early clinical development for the eye and CNS programs. The companies plan to advance programs directed to 30 targets and introduce many into clinical development during the initial five-year discovery period, which includes an option to extend. For each program, Regeneron will provide Alnylam with $2.5M in funding at program initiation and an additional $2.5M at lead candidate identification, translating to the potential for approximately $30M in annual discovery funding to Alnylam as the alliance reaches steady state. The alliance and equity-related agreements are subject to customary closing conditions and clearances, including clearance under the Hart-Scott Rodino Antitrust Improvements Act.

ALNY

Alnylam

$92.76 /

+1.38 (+1.51%)

REGN

Regeneron

$408.75 /

+2.18 (+0.54%)

  • 10

    Apr

  • 25

    Apr

  • 28

    Apr

  • 13

    May

  • 26

    Jun

ALNY Alnylam
$92.76 /

+1.38 (+1.51%)

03/06/19 Evercore ISI
Alnylam upgraded to Outperform from In Line at Evercore ISI
03/06/19 Evercore ISI
Alnylam upgraded to Outperform from In Line at Evercore ISI
03/06/19 Piper Sandler
Alnylam's givosiran looks approvable on Phase 3 data, says Piper Jaffray
03/05/19
Fly Intel: Top five analyst upgrades
REGN Regeneron
$408.75 /

+2.18 (+0.54%)

04/01/19 Piper Sandler
Aslan data show comparable activity to Dupixent, says Piper Jaffray
03/27/19 Berenberg
Merus initiated with a Buy at Berenberg
03/18/19 Piper Sandler
Piper pokes holes in Dermira data, says buy Regeneron on selloff
03/18/19 Mizuho
Dermira shares may rally to $15 or higher on today's data, says Mizuho

TODAY'S FREE FLY STORIES

Hot Stocks
Third Point urges Prudential plc to separate U.S. and Asian businesses » 12:39
02/24/20
02/24
12:39
02/24/20
12:39
PUK

Prudential plc

$37.42 /

-0.97 (-2.53%)

Third Point LLC, a New…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:36
02/24/20
02/24
12:36
02/24/20
12:36
UNH

UnitedHealth

$278.79 /

-22.465 (-7.46%)

, AAPL

Apple

$299.15 /

-13.87 (-4.43%)

, NKE

Nike

$96.11 /

-4.13 (-4.12%)

, GILD

Gilead

$72.41 /

+2.71 (+3.89%)

, BRK.A

Berkshire Hathaway

$334,500.00 /

-9250 (-2.69%)

, DAL

Delta Air Lines

$53.61 /

-4.26 (-7.36%)

, AAL

American Airlines

$25.13 /

-2.7 (-9.70%)

, JBLU

JetBlue

$19.28 /

-1.34 (-6.50%)

, LUV

Southwest

$53.95 /

-2.58 (-4.56%)

, UAL

United Airlines

$74.99 /

-3.03 (-3.88%)

, INTU

Intuit

$286.06 /

-11.71 (-3.93%)

, NGM

NGM Biopharmaceuticals

$19.45 /

+3.45 (+21.56%)

, VHC

VirnetX

$5.45 /

+0.45 (+9.00%)

, KOS

Kosmos

$4.25 /

-0.72 (-14.50%)

, EPZM

Epizyme

$21.00 /

-3.89 (-15.63%)

Stocks have been sharply…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Netflix rolling out new Top 10 feature » 12:35
02/24/20
02/24
12:35
02/24/20
12:35
NFLX

Netflix

$365.99 /

-14.09 (-3.71%)

Netflix said in a blog…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Norwegian Cruise Line put volume heavy and directionally bearish » 12:35
02/24/20
02/24
12:35
02/24/20
12:35
NCLH

Norwegian Cruise Line

$42.79 /

-4.175 (-8.89%)

Bearish flow noted in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Mosaic call volume above normal and directionally bullish » 12:25
02/24/20
02/24
12:25
02/24/20
12:25
MOS

Mosaic

$18.89 /

-0.3 (-1.56%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Fly Intel: What to watch in HP Inc.'s earnings report » 12:22
02/24/20
02/24
12:22
02/24/20
12:22
HPQ

HP Inc.

$22.10 /

-0.58 (-2.56%)

, XRX

Xerox

$34.53 /

-1.82 (-5.01%)

HP Inc. (HPQ) is…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Credit Karma deal would be valuation supportive for LendingTree, says Stephens » 12:20
02/24/20
02/24
12:20
02/24/20
12:20
TREE

LendingTree

$336.18 /

-1.11 (-0.33%)

Stephens analyst John…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Blizzard cancels Overwatch League matches in South Korea amid coronavirus fears » 12:17
02/24/20
02/24
12:17
02/24/20
12:17
ATVI

Activision Blizzard

$62.40 /

-0.97 (-1.53%)

Activision…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Technical Analysis
NASDAQ market internals summary » 12:17
02/24/20
02/24
12:17
02/24/20
12:17
$NSD

NASDAQ Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Technical Analysis
NYSE market internals summary » 12:16
02/24/20
02/24
12:16
02/24/20
12:16
$NYE

NYSE Market Internals

$0.00 /

+ (+0.00%)

Volume is above average…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Conference/Events
Wolfe Research tech strategist to hold an analyst/industry webcast » 12:14
02/24/20
02/24
12:14
02/24/20
12:14

Tech Strategist…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Hot Stocks
Novartis down 4% after ASRS reportedly sees negative side effects for Beovu » 12:08
02/24/20
02/24
12:08
02/24/20
12:08
NVS

Novartis

$93.28 /

-3.47 (-3.59%)

According to a report by…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Options
Pan American Silver call volume above normal and directionally bullish » 12:05
02/24/20
02/24
12:05
02/24/20
12:05
PAAS

Pan American Silver

$25.48 /

+0.265 (+1.05%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
VirnetX reports Supreme Court rejects Apple's appeal in $440M lawsuit » 12:04
02/24/20
02/24
12:04
02/24/20
12:04
AAPL

Apple

$299.00 /

-14.02 (-4.48%)

, VHC

VirnetX

$5.62 /

+0.62 (+12.40%)

VirnetX (VHC) announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
eBay Canada, Shippo renew partnership for shipping services » 12:03
02/24/20
02/24
12:03
02/24/20
12:03
EBAY

eBay

$37.05 /

-1.145 (-3.00%)

eBay Canada and Shippo…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
IAMGold rises 12.0% » 12:00
02/24/20
02/24
12:00
02/24/20
12:00
IAG

IAMGold

$3.51 /

+0.365 (+11.62%)

IAMGold is up 12.0%, or…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Piper more positive on Regeneron after ASRS warns on competing drug » 12:00
02/24/20
02/24
12:00
02/24/20
12:00
NVS

Novartis

$93.39 /

-3.36 (-3.47%)

, REGN

Regeneron

$388.16 /

-15.71 (-3.89%)

Piper Sandler analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Britannia Bulk rises 14.0% » 12:00
02/24/20
02/24
12:00
02/24/20
12:00
DWT

Britannia Bulk

$5.77 /

+0.715 (+14.14%)

Britannia Bulk is up…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

Hot Stocks
ProShares Trust Ultra VIX Short Term Futures ETF rises 21.4% » 12:00
02/24/20
02/24
12:00
02/24/20
12:00
UVXY

ProShares Trust Ultra VIX Short Term Futures ETF

$15.00 /

+2.67 (+21.65%)

ProShares Trust Ultra VIX…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Options
ServiceNow put volume heavy and directionally bearish » 11:55
02/24/20
02/24
11:55
02/24/20
11:55
NOW

ServiceNow

$332.01 /

-12.39 (-3.60%)

Bearish flow noted in…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

General news
Treasury's $84 B 3- and 6-month bill auctions were well received » 11:55
02/24/20
02/24
11:55
02/24/20
11:55

Treasury's $84 B 3-…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

Conference/Events
Aldeyra to host research and development day » 11:55
02/24/20
02/24
11:55
02/24/20
11:55
ALDX

Aldeyra

$5.04 /

-0.01 (-0.20%)

Research &…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
MCO, hospital stocks under pressure as Sanders wins Nevada » 11:54
02/24/20
02/24
11:54
02/24/20
11:54
ANTM

Anthem

$279.64 /

-15.17 (-5.15%)

, CNC

Centene

$59.80 /

-5.61 (-8.58%)

, CVS

CVS Health

$68.62 /

-2.88 (-4.03%)

, HUM

Humana

$349.59 /

-20.06 (-5.43%)

, MOH

Molina Healthcare

$139.01 /

-10.81 (-7.22%)

, UNH

UnitedHealth

$280.73 /

-20.525 (-6.81%)

, QRTEA

Qurate Retail

$8.95 /

-0.33 (-3.56%)

, AMZN

Amazon.com

$2,003.58 /

-90.71 (-4.33%)

, AAPL

Apple

$299.95 /

-13.07 (-4.18%)

, ROKU

Roku

$113.35 /

-6 (-5.03%)

, THC

Tenet

$32.53 /

-1.65 (-4.83%)

, HCA

HCA Healthcare

$141.18 /

-6.86 (-4.63%)

, CYH

Community Health

$6.27 /

-0.91 (-12.67%)

Shares of Managed Care…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Recommendations
Pilgrim's Pride price target lowered to $27 from $30 at Goldman Sachs » 11:52
02/24/20
02/24
11:52
02/24/20
11:52
PPC

Pilgrim's Pride

$22.93 /

-1.34 (-5.52%)

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Hot Stocks
Aerojet Rocketdyne announces $63.2M award from U.S. Navy » 11:51
02/24/20
02/24
11:51
02/24/20
11:51
AJRD

Aerojet Rocketdyne

$52.98 /

-1.245 (-2.30%)

Aerojet Rocketdyne has…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.